Targeted delivery and sustained release of any API using any formulation modality
Why NovochizolTM ?
Research and Development
Targeted, intracellular drug delivery
NovochizolTM technology can deliver all classes of APIs - small molecules, peptides, nucleic acids and large proteins - inside different cells, only at the site of administration. It opens a world of possibilities for all active ingredients to reach new targets.
Hyperhidrosis (Botulinum toxin)
Injectable NovochizolTM formulations of botulinum toxin prolong inhibition of excessive transpiration by at least 200%. They also offer the promise of injection-free, topical administration
Atrial Fibrillation (Botulinum toxin)
NovochizolTM - formulated botulinum toxin injections into epicardial fat pads lead to long-term suppression of atrial fibrillation and complete abolition of cardiac vagal response.
Formulation of poorly soluble APIs for multiple indications
NovochizolTM technology can help formulate APIs when all other approaches have failed. A collaboration with Boehringer-Ingelheim is under way to formulate five drug candidates with diverse properties and a range of mechanistic targets.
Resistant Hypertension (Botulinum toxin)
NovochizolTM - formulated botulinum toxin injections into renal arteries inhibit renin release, resulting in lower arterial blood pressure over extended periods of time. NovochizolTM enables a new mechanism of action.
Oncology: Targeted therapies and immuno-therapies
Thanks to tissue-adherence of NovochizolTM -formulated APIs at the site of administration, our technology offers an unprecedented potential to deliver virtually any anti-cancer drug only where it is needed.